In summary, we have observed that Ganweikang tablet can improve liver lesions in a mouse model of NAFL and NASH by modulating inflammation, apoptosis, and fatty acid oxidation through inhibiting NFκB, inactivating caspase3/8, and activating PPARα, which indicates Ganweikang tablet not only as a drug candidate but also provides a theoretical basis of Ganweikang tablet in the treatment of NAFLD. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.